Status:
COMPLETED
Study With Oral Isovue in Abdominopelvic CT
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
Eligibility:
All Genders
Brief Summary
This is a retrospective clinical study with prospectively designed blinded evaluation of CT images in adult and pediatric patients who underwent CT examinations of the abdomen and pelvis and were oral...
Eligibility Criteria
Inclusion
- Patients will be included in the study if:
- Demographic and safety data are available for analysis
- Complete set of CT images performed after oral administration of Isovue-300 are available for assessment
- Isovue-300 was orally administered during an interval time of 60-20 minutes before the CT scanning.
- Patients will be excluded from the study if:
- Oral contrast agent received within 1 week prior to the CT scan
- Undergone any abdominopelvic surgery procedure that resulted in alteration of the bowel transit time prior to the CT exam
- CT exam with oral administration of Isovue was performed because of a known or suspected condition of bowel obstruction
- Patient did not actively drink the contrast solution.
Exclusion
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT04453059
Start Date
July 1 2021
End Date
July 1 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akron Children's Hospital
Akron, Ohio, United States, 44308